Inphenacin 10mg (Solifenacin Succinate)

Adult dose

The usual recommended dose for adults (including older adults) is 5mg once daily. If necessary, the dose may be increased to a maximum of 10mg once daily. This drug may be taken regardless of meals and should be swallowed whole with water. Dose adjustment is required for the following patients. 1. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance>30ml/min). Use with caution in patients with severe renal impairment (creatinine clearance≤30ml/min), and do not exceed 5mg once daily. 2. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. Use with caution in patients with moderate hepatic impairment (Child-Pugh class B), and do not exceed 5mg once daily. 3. Patients receiving a potent cytochrome P450 3A4 (CYP3A4) inhibitor In patients receiving ketoconazole or another potent CYP3A4 inhibitor (e.g., ritonavir, nelfinavir, itraconazole), limit the maximum daily dose to 5mg.

This drug should not be used in patients with symptoms of poor urine excretion. Patients with severe gastrointestinal problems or significant muscle weakness should also not be administered this drug. Patients with glaucoma or allergies to this drug should not take it. Patients on hemodialysis or those with severe liver or kidney dysfunction should avoid taking it. This drug is also not suitable for patients genetically unable to digest certain sugars. Caution is required for patients with a risk of urinary obstruction or slow gastrointestinal motility. Patients with moderate to severe renal or hepatic impairment should have their dosage limited, and caution is needed when taken with certain drugs. This drug may cause various side effects such as dry mouth, constipation, blurred vision, difficulty urinating, dry eyes, peripheral edema, fatigue, cough, hypertension, nausea, indigestion, abdominal pain, vomiting, influenza, pharyngitis, dizziness, depression, urinary difficulty, reduced urine flow, post-void bladder sensation, urinary tract infection, cystitis, rhinopharyngitis, headache, hallucinations, drowsiness, delirium, urinary retention, renal impairment, itching, rash, erythema multiforme, exfoliative dermatitis, atrial fibrillation, palpitations, tachycardia, and QT prolongation on ECG. In severe cases, bowel obstruction, vascular edema, or allergic reactions may occur, therefore, immediate consultation with medical personnel is necessary if symptoms arise. Caution is required when driving or operating machinery due to potential drowsiness or blurred vision. When taken with other anticholinergic drugs, the effects may be enhanced or side effects may become more severe. As this drug is metabolized in the liver, it may increase drug concentration when used with certain liver metabolic enzyme inhibitors, necessitating dosage adjustment. The safety of this drug during pregnancy is not established, so caution is advised during administration, and it is better to avoid use while breastfeeding. Safety and efficacy have not been established in children, so it should not be administered to them. In case of overdose, appropriate treatment such as administering activated charcoal is needed without inducing vomiting, and specialized treatment is required for severe central nervous system symptoms or heart problems.

• Dry mouth
• constipation
• blurred vision
• urinary retention
• dry eyes
• fecal impaction
• colon obstruction
• intestinal obstruction
• angioneurotic edema
• nausea

This drug should be stored in a tightly closed container to protect it from air and light, and it is safe to store at room temperature between 1 and 30 degrees Celsius. Proper storage like this helps maintain the drug's effectiveness and prevents deterioration.

Appearance

Light pink round film-coated tablet

Package unit

PTP packaging - 100 tablets/PTP [(10 tablets/PTP*10)]